Both treatments operate through entirely different mechanisms and target separate physiological systems, minimising the likelihood of pharmacological interaction
She recovered uneventfully and later acknowledged omitting semaglutide use from her medical history because she did not consider it a medication. Conclusion This case demonstrates that even stricter dietary measures than those recommended in current guidelines may not eliminate aspiration risk in GLP-1-RA users
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release
We consider your medical history, lifestyle, and weight loss goals to create a program that suits you best
Investigators DT, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al